<DOC>
	<DOCNO>NCT02743182</DOCNO>
	<brief_summary>Chronic hepatitis B ( CHB ) affect 350 million people worldwide . The common form Europe CHB HBeAg-negative . Antiviral treatment CHB HBeAg-negative patient include chronic administration nucleos ( ) ide analogue ( NUC ) pegylated interferon ( PegIFN ) 12 month . Typically , PegIFN allow immune control CHB antigen `` '' ( HBsAg ) loss around 4 % patient compare less 0,1 % use NUC . Recently , describe HBsAg quantification ( HBsAg-q ) useful identify patient high probability lose HBsAg follow-up . In addition , proof-of-concept study nine HBeAg-negative patient receive NUC show add PegIFN ( 16 week ) achieve HBsAg loss one patient ( 11 % ) . The aim study evaluate efficacy safety add PegIFN ( 48 week ) treat HBeAg-negative patient NUC .</brief_summary>
	<brief_title>HBsAg Loss Adding Pegylated Interferon HBeAg-negative Patients</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis B</mesh_term>
	<mesh_term>Hepatitis B , Chronic</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<mesh_term>Peginterferon alfa-2a</mesh_term>
	<criteria>Chronic hepatitis B ( HBeAgnegative ) Signed inform consent Aged &gt; 18 Contraindications Pegylated interferon ( cirrhosis , pregnancy , others ) Previous treatment interferon Pegylated interferon Previous HBsAg loss Treatment duration Nucleos ( ) ide analogues less 2 year Poor adherence Nucleos ( ) ide analogue</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2016</verification_date>
</DOC>